Table 1.
NCI Cohort Consortium strategic initiatives (2018–2021).
| GOALS | ||||
|---|---|---|---|---|
| Communication | Career development | Research facilitation | Leverage cohorts to fill scientific gaps | Address common challenges | 
| Increase the exchange of information and enhance member engagement | Provide networking and educational opportunities for early career investigators | Advance cohort consortia specific research. | Promote collaborative research, particularly on cancer incidence and outcomes for rare cancers, cancer subtypes, and rare exposures, not easily addressed in a single cohort study | Identify and address common methodologic challenges in cohort research | 
| STRATEGIES | ||||
| Increase the exchange of information at the annual meeting by including interactive sessions and more time for discussion during working group meetings. | Create opportunities for leadership roles within the steering committee and working groups for early career investigators. | Enhance technology infrastructure to support data sharing and harmonization, including CEDCDa, CMRb, controlled-access data repositories, and other options (e.g., cloud-based files that can be queried). | Identify and address specific research gaps across the cancer continuum. | Develop, validate and share linkage algorithms for a variety of exposures and outcomes from a variety of sources (e.g., electronic medical records, registries, geospatial databases). | 
| Promote data sharing through CEDCDa, CMRb, and accessible controlled-access data repositories, via website, portal, and at scientific meetings. | Assess feasibility (and implement if appropriate) of creating a centralized cohort tissue repository. | Develop and share algorithms for harmonization of commonly used data elements. | ||
Provide regular updates in a monthly newsletter and a centralized portal about:
  | 
Support opportunities for early career investigators to be invited speakers at the annual meeting. | Provide templates of standardized data sharing agreements (DTAc, DUAd, MTAe) and informed consent language regarding data sharing. | Identify and address research gaps for:
  | 
Develop and validate new methodologies. Apply existing methodologies to study rare cancers, cancer subtypes, cancer outcomes, and rare exposures. | 
| Develop a process for fostering collaboration between early career and senior investigators (i.e., matching them in working groups at the annual meeting). | Leverage cloud-based technology to provide comprehensive lists of data that have been harmonized, including which working groups have harmonized data. | Develop procedures for validation of measurement instruments, including questionnaire and biomarker data. | ||
| Develop and implement, as appropriate, incentives to encourage involvement of early career investigators in working groups. | Assess feasibility (and implement if appropriate) of creating a centralized data repository. | Develop standard procedures for calibration in pooled analyses. | ||
| Evaluate the feasibility (and implement if appropriate) of developing a new cohort/member orientation video. | Develop publication policy for acknowledgement of the NCI Cohort Consortium projects and working groups. | Identify and share best practices for participant engagement and retention. | ||
| Support webinars and other mechanisms to foster exchange of best practices (e.g., data, biospecimen and tissue collection, and data harmonization) and provide working group progress updates. | Support novel approaches and methods to support project managers, and data harmonization for new and existing work groups. | |||
| Incentivize data sharing and preparation. | ||||
| Develop a system to track project activities, publications, and for submission of new project proposals. | ||||
aCEDCD: Cancer Epidemiology Descriptive Cohort Database.
bCMR: Cohort Metadata Repository.
cDTA: Data Transfer Agreement.
dDUA: Data Use Agreement.
eMTA: Material Transfer Agreement.
- Rare cancers, multiple primaries or cancers with changing incidence over time.
 - Rare exposures or exposures that change over time.
 - Health disparities.
 - Molecular heterogeneity within cancer types and common molecular signatures across different types of cancer.
 - Use of geospatial data in cohort study research.
 - Gene–environment interactions, especially for rare cancers or cancer subtypes.
 - Impact of co-morbidities (e.g., diabetes) and their treatment on cancer outcomes.
 - Understanding the different dynamics of exposures - aging vs. change in exposure (e.g., early-age weight gain vs. older-age weight loss).
 - Accelerated aging among cancer survivors and the long-term effects of treatment.
 - Other “omic” exposures (e.g., metabolome, microbiome, epigenome).
 - Potential use of cohorts for the study of early detection biomarkers.
 - Long-term outcomes among cancer survivors.